Acarix Reports Significant Progress Toward Fixed Reimbursement

Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another milestone on its path toward fixed reimbursement in the U.S. healthcare market.

Three of the five largest payors in the country have removed the “experimental and investigational” designation for CADScor® and lifted prior authorization requirements for reimbursement. While this does not yet constitute fixed reimbursement, it represents a major advancement in the process, where physicians are now seeing consistent payments for usage of CADScor® with these three national payors.